[go: up one dir, main page]

MXPA05006981A - Derivados de prostaglandinas para el tratamiento de la molestia abdominal. - Google Patents

Derivados de prostaglandinas para el tratamiento de la molestia abdominal.

Info

Publication number
MXPA05006981A
MXPA05006981A MXPA05006981A MXPA05006981A MXPA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A
Authority
MX
Mexico
Prior art keywords
prostaglandins
derivatives
abdominal discomfort
treating abdominal
chloride channel
Prior art date
Application number
MXPA05006981A
Other languages
English (en)
Inventor
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05006981(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA05006981A publication Critical patent/MXPA05006981A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe el uso novedoso de un abridor del canal del cloruro, especialmente un compuesto de prostaglandina para el tratamiento de la molestia abdominal; se describe ademas, el uso novedoso de un abridor del canal del cloruro, especialmente un compuesto de prostaglandina para el tratamiento de trastornos gastrointestinales funcionales.
MXPA05006981A 2002-12-27 2003-12-26 Derivados de prostaglandinas para el tratamiento de la molestia abdominal. MXPA05006981A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43646302P 2002-12-27 2002-12-27
US43646202P 2002-12-27 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (1)

Publication Number Publication Date
MXPA05006981A true MXPA05006981A (es) 2005-12-14

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006981A MXPA05006981A (es) 2002-12-27 2003-12-26 Derivados de prostaglandinas para el tratamiento de la molestia abdominal.

Country Status (15)

Country Link
US (3) US7795312B2 (es)
EP (2) EP2281564A3 (es)
JP (2) JP4889219B2 (es)
KR (2) KR20120045051A (es)
CN (1) CN1753680B (es)
AR (1) AR042670A1 (es)
AU (1) AU2003292556B2 (es)
BR (1) BRPI0317740B8 (es)
CA (1) CA2510051C (es)
ES (1) ES2591252T3 (es)
MX (1) MXPA05006981A (es)
NO (1) NO335441B1 (es)
NZ (1) NZ541110A (es)
TW (1) TWI336254B (es)
WO (1) WO2004060377A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
JP5294559B2 (ja) * 2003-07-03 2013-09-18 スキャンポ・アーゲー クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR20140069182A (ko) * 2005-04-12 2014-06-09 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자 펌프 억제제의 병용
EP2059247A1 (en) 2006-09-06 2009-05-20 Sucampo AG Method and composition for promoting gastrointestinal bicarbonate secretion
EP2114411A2 (en) * 2007-02-27 2009-11-11 Sucampo AG Composition and method for protecting mitochondria
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
KR20120092592A (ko) * 2009-09-18 2012-08-21 아돌로 코포레이션 위장관 질환을 위한 오피오이드 수용체 길항제의 용도
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN104379140A (zh) * 2012-04-23 2015-02-25 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
NZ706738A (en) 2012-10-15 2018-10-26 Epizyme Inc Substituted benzene compounds
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
TW249226B (es) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2041417C (en) * 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
PT978284E (pt) * 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
ATE402925T2 (de) * 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
ATE387204T1 (de) 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt
CA2458471C (en) 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener

Also Published As

Publication number Publication date
BR0317740A (pt) 2005-11-22
CN1753680A (zh) 2006-03-29
TWI336254B (en) 2011-01-21
KR101164838B1 (ko) 2012-07-11
JP2012031202A (ja) 2012-02-16
BRPI0317740B1 (pt) 2018-09-18
KR20120045051A (ko) 2012-05-08
EP1575596B1 (en) 2016-06-22
US20040138308A1 (en) 2004-07-15
KR20050086950A (ko) 2005-08-30
CA2510051C (en) 2016-07-05
JP2006513232A (ja) 2006-04-20
WO2004060377A1 (en) 2004-07-22
CA2510051A1 (en) 2004-07-22
EP2281564A3 (en) 2012-09-05
AR042670A1 (es) 2005-06-29
AU2003292556A1 (en) 2004-07-29
CN1753680B (zh) 2010-12-08
BRPI0317740B8 (pt) 2021-05-25
US20100298424A1 (en) 2010-11-25
EP1575596A1 (en) 2005-09-21
NZ541110A (en) 2008-11-28
NO20053623L (no) 2005-09-26
US20130217770A1 (en) 2013-08-22
JP4889219B2 (ja) 2012-03-07
AU2003292556B2 (en) 2009-09-10
ES2591252T3 (es) 2016-11-25
NO20053623D0 (no) 2005-07-26
NO335441B1 (no) 2014-12-15
US7795312B2 (en) 2010-09-14
TW200418491A (en) 2004-10-01
EP2281564A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
MXPA05006981A (es) Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
DE60329001D1 (en) 8-hydroxychinolinderivate
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
SI1485360T1 (sl) Blokatorji natrijevih kanalov
BE2012C040I2 (es)
GB0225475D0 (en) Therapeutic agents
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
SI1694318T1 (sl) (S)-2-N-propilamino-5-hidroksitetralin kot terapevtsko sredstvo z agonističnim učinkom na D3
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MY138263A (en) Therapeutic chroman compounds
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
EP1656127A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
SG139747A1 (en) Inhibitors of the mutant form of kit
TW200508199A (en) Novel compound
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SE0101082D0 (sv) Novel use
EP1532131A4 (en) COMPOUNDS OF THE MOTILID TYPE
SE0200198D0 (sv) New use
GB0129457D0 (en) Method of treatment
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general